Navigation Links
3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/21/2013

TVB-2640, is one of a series of FASN inhibitors initially being developed by 3-V to treat solid tumor cancers by inhibiting key metabolic and signaling pathways associated with tumor growth and proliferation.  FASN activity promotes the tumorigenic potential of cells as part of tumor cell metabolism, which in turn provides fuel required by rapidly proliferating cancer cells.  FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers.

3-V has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and plans to initiate first-in-human studies of TVB-2640 by the end of 2013.

Data for 3-V's FASN tumor metabolism inhibitors was presented during the Therapeutic Agents: session of the Molecular Targets and Cancer Therapeutics meeting on Monday at 12:30 pm ET in a poster titled "Characterization of small-molecule FASN inhibitors in preclinical tumor models" (Abstract #B261)

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The
3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

 

Contact information'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
(Date:12/19/2014)... 20, 2014 Today, Balfleet.com , ... outfits, announces its formal dress promotion. All the old ... to 60% off. , Balfleet.com is well-known for its ... dresses, prom dresses, cocktail dresses and more. Its formal ... money-back guarantee, and they can create an elegant look ...
(Date:12/19/2014)... Energy Textiles is excited to announce ... the world’s leading responsive textile, can now be ... are a number of benefits to wearing Celliant, ... balanced body temperature; which can lead to enhanced ... athletic performance; and overall wellness. In addition, the ...
Breaking Medicine News(10 mins):Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2
... , PROVO, Utah, Aug. 7 Nu ... board of directors has declared a quarterly dividend of $0.115 per ... of record on Aug. 28, 2009. , , ... Inc. has been demonstrating its tradition of innovation through its comprehensive ...
... , , NEW YORK, Aug. 7 ... Duane Reade Inc. and Duane Reade (collectively, the "Issuers"), had ... Senior Secured Notes due August 1, 2015 (the "Notes"). ... The Notes were priced at 97.417%, representing a yield ...
... focusing on heavier children may miss the target, study ... cholesterol testing guidelines for children may have to be ... isn,t an effective indicator of high cholesterol in kids. ... issued revised cholesterol screening guidelines that recommended a cholesterol ...
... , , , , ... WBMD ) and HLTH Corporation (Nasdaq: HLTH ) today announced ... 29th Annual Global Growth Conference on Wednesday, August 12, 2009 at 1:00 ... the general public are invited to listen to a live audio broadcast ...
... keep new beta cells under control , FRIDAY, Aug. 7 ... that plays a key role in the conversion of pancreas ... to a new treatment for type 1 diabetes. , In ... called Pax4 is turned on in pancreatic cells, the cells ...
... W.Va., Aug. 7 The first national study of homeless people,s ... to arrive at the hospital by ambulance and more than twice ... of homeless patients arrived by ambulance -- at an estimated cost ... Analyzing almost half a million emergency room visits by ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:Cholesterol Screening Shouldn't Rely on Kids' Weight 2Health News:Researchers Produce First Nationwide Study of Homeless in ERs 2
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
... a four channel Platelet Aggregation Profiler with ... assay (Ristocetin cofactor), platelet aggregation and leukocyte ... for the evaluation and confirmation of Heparin ... tests to be run simultaneously and independently. ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Medicine Products: